Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has shared an update.
Lumos Diagnostics Holdings Ltd. has issued 88,888,876 fully paid ordinary shares at an issue price of A$0.225 per share, expanding its capital base without a disclosure document under section 708A(5) of the Corporations Act 2001. The company confirmed it is compliant with relevant financial reporting and continuous disclosure obligations and that there is no excluded information requiring disclosure, providing reassurance to investors about regulatory compliance around the new share issuance.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. is a medical technology company specializing in rapid point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. The company provides customized assay development and manufacturing services, proprietary digital reader platforms, and develops, manufactures, and commercializes Lumos-branded point-of-care tests targeting infectious and inflammatory diseases.
Average Trading Volume: 4,421,380
Technical Sentiment Signal: Buy
Current Market Cap: A$168.6M
See more insights into LDX stock on TipRanks’ Stock Analysis page.